Head of global pharma group suggests pandemic ‘social contract’
The president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) says rich industrialised countries and the pharmaceutical industry must prepare for the next pandemic. Critical of vaccine nationalism, Thomas Cueni wants to ensure that poorer countries get access to vaccines faster when crises hit.
This content was published on
2 minutes
www.swissinfo.ch/ds
العربية
ar
رئيس مجموعة شركات الأدوية العالمية يقترح «عقدا اجتماعيا» لمكافحة الأوبئة
What is needed is a kind of social contract, argues Cueni in an interview published by the SonntagsZeitung newspaper. He says industry is prepared to reserve part of the production for poorer countries. In return, rich countries must provide initiatives like COVAX (COVID-19 Vaccine Global Access Facility) with enough funding to buy the reserved production.
Vaccination priority should be given to people who work in healthcare or are over 65 years old, he says, respectively 1% and 8% of the global population.
“A willingness on the part of companies to reserve part of the production for these population groups in poorer countries right from the start in the event of a pandemic could be a real game changer,” he says.
Vaccine nationalism
Cueni notes that rich countries engaged in a kind of hedging at the beginning of the Covid-19 pandemic. They ordered all promising vaccines to ensure they have the vaccine that ultimately gets approved. Then they hoarded vaccines on a large scale. “This vaccine nationalism was the big problem,” he says.
Africa, in particular, was left behind. “Therefore, by 2040, Africa wants to cover around 60% of its vaccination needs from its own production,” he notes. “But that doesn’t happen overnight, because an entire infrastructure has to be set up.”
The costs of a pandemic preparedness fund pale in comparison with the costs of the pandemic, he notes, citing calculations by the International Monetary Fund (IMF). Such a fund would require around $20 billion. The Covid-19 pandemic is expected to cost $13.8 trillion by 2024.
Based in Geneva, IFPMA represents the biopharmaceutical industry at the global level. Cueni has been at the helm of the organisation since 2017, having previously served as secretary general of Interpharma, the association of pharmaceutical research companies in Switzerland.
This content was published on
A majority of Swiss citizens have open attitudes towards various infertility treatments, including even egg donation, which is currently prohibited.
Reports of Swiss cyber fraud almost doubled in six months
This content was published on
The head of the new Federal Office for Cybersecurity (FOC), Florian Schütz, has presented a new strategy after just over four months in office.
Ecological status of Swiss streams insufficient according to study
This content was published on
Pesticide use and obstructions of waterways have a particularly negative impact on sensitive organisms, completely absent in 70% of streams analysed.
Train line between Brig and Domodossola interrupted
This content was published on
One day after a derailment approximately 15 kilometres from the Swiss border, BLS is running buses for passengers between Preglia and Domodossola, in Italy.
Swiss football boss wants crackdown on individual hooligans
This content was published on
The head of the Swiss Football League says he prefers a harsher approach to individual hooligans rather than collective punishment measures affecting all fans.
Amherd: Council of Europe is ‘as urgently needed as ever’
This content was published on
The Swiss government emphasised on Sunday the vital role of the Strasbourg-based Council of Europe, 75 years after it was founded.
Swiss minister: Italy will back Switzerland in EU talks
This content was published on
Bern can count on the backing of Italy as it re-enters talks with the European Union on future relations, Viola Amherd says.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid-19: Switzerland can smile again. But for how long?
This content was published on
While Switzerland is back to normal, countries like China struggle to contain the pandemic. Elsewhere, people haven't received their first jab yet.
This content was published on
Public health experts are cautious about lifting Covid-19 restrictions. One key reason is that we still can't test for our immunity to the virus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.